A Randomized, Double-Blind, Placebo-Controlled Single-Ascending Dose and Multiple-Ascending Dose Phase 1 Study of SL-325 in Healthy Volunteers
Latest Information Update: 22 Jun 2026
At a glance
- Drugs SL 325 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; First in man
- Sponsors Shattuck Labs
Most Recent Events
- 08 Jun 2026 Results presented in a Shattuck Labs Media Release.
- 05 Jun 2026 According to Shattuck Labs media release, the data from the trial will be presented in an investor call and webcast.
- 30 Apr 2026 Status changed from recruiting to active, no longer recruiting.